Barzolvolimab
Barzolvolimab (CDX 0159) is a humanized anti-KIT IgG1 monoclonal antibody. Barzolvolimab specificity and potently inhibits KIT activation by SCF. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria[1].
Product Specifications
CAS Number
[2438203-51-9]
Product Name Alternative
CDX-0159; CDX-0158
UNSPSC
12352203
Target
C-Kit
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/barzolvolimab.html
Purity
99.83
Solubility
H2O
Smiles
[Barzolvolimab]
Molecular Weight
(145.1 kDa)
References & Citations
[1]Terhorst-Molawi D, et, al. Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. Allergy. 2022 Nov 16.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS7023477-01 0.02 mg
Recombinant Haemophilus influenzae Na(+)-translocating NADH-quinone reductase subunit C
Ask
View Details MBS7023477-02 0.1 mg
Recombinant Haemophilus influenzae Na(+)-translocating NADH-quinone reductase subunit C
Ask
View Details 
MBS7023477-03 5x 0.1 mg
Recombinant Haemophilus influenzae Na(+)-translocating NADH-quinone reductase subunit C
Ask
View Details